Topline results were announced from a phase 3 study evaluating Moderna’s cytomegalovirus (CMV) vaccine candidate, mRNA-1647.
Small study looks only at a cardiac biomarker; findings are in line with reduced myocarditis risk in mRNA COVID vaccines ...
Key opinion leaders previously interviewed by GlobalData noted the need for more data on current RSV vaccines and their use ...
Lung cancer and melanoma patients immunized with this formula doubled their chances of surviving three years, according to a ...
The US National Security Agency hacked China’s National Time Service Center over several years, the Chinese counter-espionage agency has claimed. China has accused the US National Security Agency (NSA ...
An mRNA cancer vaccine carries its own immune booster and lights up when it starts working, showing treatment success in mice ...
CAMBRIDGE, MA / ACCESS Newswire / October 19, 2025 / Moderna, Inc. (NASDAQ:MRNA) today announced data regarding two of its ...
The Chosun Ilbo on MSN
Moderna's Updated COVID-19 Vaccine Essential Against Emerging Variants
Over the past five years, 800 million people worldwide have been infected with COVID-19. The death toll has reached 7 million. Fatalities continue to occur even now. COVID-19 is now trending toward ...
Studies are sounding alarm bells regarding the safety of COVID-19 mRNA vaccines, particularly in light of new findings linking these injections to an increased risk of myocarditis, a potentially fatal ...
A team of researchers from Yong Loo Lin School of Medicine, National University of Singapore (NUS Medicine) and Tsinghua ...
Scientists in Japan have developed a new mRNA vaccine that could one day make it easier and more comfortable to treat a common cause of vision loss in older adults. The vaccine has shown strong ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback